News

Net loss of Nath Bio-Genes (India) reported to Rs 0.01 crore in the quarter ended March 2026 as against net profit of Rs 1.48 crore during the previous quarter ended March 2025. Sales declined 0.73% to Rs 51.59 crore in the quarter ended March 2026 as against Rs 51.97 crore during the previous quarter ended March 2025.For the full year,net profit rose 7.85% to Rs 41.63 crore in the year ended March 2026 as against Rs 38.60 crore during the previous year ended March 2025. Sales rose 21.98% to Rs 445.10 crore in the year ended March 2026 as against Rs 364.91 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales51.5951.97 -1 445.10364.91 22 OPM %8.680.81 -11.7813.64 - PBDT2.262.91 -22 44.2643.86 1 PBT1.231.57 -22 40.2940.04 1 NP-0.011.48 PL 41.6338.60 8 Powered by Capital Market - Live News

Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 4 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 4 May 2026.

Net profit of Nath Bio-Genes (India) declined 39.62% to Rs 1.60 crore in the quarter ended December 2025 as against Rs 2.65 crore during the previous quarter ended December 2024. Sales rose 78.90% to Rs 65.96 crore in the quarter ended December 2025 as against Rs 36.87 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.9636.87 79 OPM %5.4321.78 - PBDT0.764.62 -84 PBT-0.213.79 PL NP1.602.65 -40 Powered by Capital Market - Live News

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live News